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expenditures were related to higher bDMARD uptake (Table), though not meeting
statistical significance (OR 1.91; 95% CI 0.93,3.92). Similar findings were found
with country GDP (OR 1.72;95% CI 0.83,3.57).
Conclusions: There remains important residual variation across countries in
bDMARD uptake of patients with SpA followed in specialized SpA centers. This
is despite adjustment of well-known factors for bDMARD use such as clinical and
country-level socio-economic factors.
Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.4480
WEDNESDAY, 14 JUNE 2017
Early diagnosis of systemic sclerosis and myositis:
biomarkers and diagnostic tool
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Background: We described the conformational PDGFRα epitope of VHPAM–
Vκ16F4 agonistic autoantibody1, cloned from memory B cells of a SSc patient,
that can induce fibrosis in vivo2. We showed that peptides composing this epitope
may be specifically recognized by serum IgG of patients with systemic sclerosis
(SSc), but not of controls.
Objectives: i. To identify the immunodominant peptide within the discontinuous
PDGFRα epitope of VHPAM–Vκ16F4; ii. to identify other immunodominant
epitopes recognized by agonistic autoantibodies; iii. to use these immunodominant
peptides to develop an epitope-based assay for diagnosis of SSc and classification
of SSc clinical subtypes.
Methods: i.The large PDGFRα peptide library used for epitope mapping of
monoclonal anti-PDGFRα antibodies1 was screened with 25 SSc (12 limited,
13 diffuse) and 25 healthy control (HC) serum samples. ii. A smaller PDGFRα
peptide library containing only the top 20 conformational binders plus 20 linear
and 20 conformational controls was synthesized. 60 conformational and linear
peptides of a cognate protein forming a molecular complex with PDGFRα were
included in the array. 20 scrambled peptides were added as negative controls.
This library was screened with the same 50 serum samples. iii. A third library
was synthesized, retaining the top cognate protein peptide binders, and 15
chimeric PDGFRα/cognate protein peptides, chosen among the best binders,
with some nonbinding controls. This library was tested as before. Libraries were
synthesized by Pepscan Presto, Netherlands. Statistical analysis was performed
by Wilcoxon-Mann-Whitney test. Correlations between serological results and
clinical status were made.
Results: i. An immunodominant peptide discriminating SSc from HC serum
samples was identified in the first library. ii. This was confirmed by the second
library, which highlighted also one immunodominant epitope from the cognate
protein. Statistical analysis identified two cohorts of SSc samples (reactive vs
nonreactive, the latter undistinguishable from HC) each composed by limited and
diffuse SSc subtypes. iii. The third peptide library identified the chimeric peptide
recognized exclusively by the reactive SSc serum samples, which were taken
from patients with active, progressive disease regardless of limited vs diffuse
classification, whereas the nonreactive SSc samples were taken from subjects
with less active, non progressive disease.
Conclusions: We developed a conformational epitope-based assay detecting
SSc-specific, agonistic, serum autoantibodies. The preliminary results suggest
that this novel array may identify SSc patients with active disease, regardless
of the canonical classification criteria. We propose this assay for prospective
screening of large cohorts of patients affected by, or suspected for, SSc, to
validate it as a tool for disease activity assessment and/or early diagnosis.
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Background:Muscle biopsy is the gold standard for the diagnosis of inflammatory
myopathies, but the role of immunohistochemistry in Necrotizing Myopathies (NM)
has not been fully characterized yet.
Objectives: To determine if MHC-I expression and pattern of C5b-9 deposition in
capillaries correlate with clinical phenotype and response to treatment in NM.
Methods: The Neuropathology Departmental database was searched to identify
patients with a histological diagnosis of NM and follow up data for at least 6
months (30 patients). Electronic patient records were reviewed retrospectively to
record demographics, autoantibodies, treatment, proximal muscle power at 3, 6
and 12 months by Manual Muscle Testing (MMT) (2), levels of CK and flares.
Patients were classified as responders when there was improvement of MMT
≥20% and non-responders when MMT improvement was <20% (3). All biopsies
were reviewed blindly by an experienced neuropathologist. MHC-I expression
was classified as positive only if over expressed in all fibers. The patterns of
C5b-9 deposition in endomysial capillaries were classified as specific (solid),
non-specific (granular) or negative.
Results: MHC-I positive group (n=16/30) had a higher proportion of responders
(62,5% vs 7,7%, p=0.002), higher number of patients with total recovery of muscle
power (66,7 vs. 15,4%) and were more commonly positive for autoantibodies
(75% vs. 35.7%, p=0.030) when compared to the MHC-I negative group (n=14).
17 patients were positive for auto-antibodies of which 9 were myositis specific
antibodies [SRP (n=6), HMG-CoA reductase (n=1), Jo-1 (n=1), P155/140 (n=1)]
and 4 were myositis associated antibodies [Ro-52 (n=2), Ku (n=1), Pm/Scl (n=1)].
13/30 patients had C5b-9 deposition, with a specific pattern in 5 and non-specific
in 8. The specific pattern group had a greater reduction of CK after 6 months
compared to non-specific and negative respectively (98% vs. 77% vs. 56.8%,
p=0.006), greater reduction in CK after 12 months (96.6% vs. 68.9% vs. 59.6%,
p=0.024) and higher rates of responders (80% vs. 60% vs. 18,8%, p=0.001). Six
patients were on immunosuppressants (azathioprine/hydroxychloroquine, n=2),
steroids (n=3) or both (n=1) for a minimum of 4 weeks when the biopsy was
performed. Differences in age, gender, clinical features or treatment were not
found to be statistically significant.
Conclusions: Upregulation of MHC I and solid staining pattern of C5b-9 in the
capillaries of NM patients appears to be associated with a better outcome.
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Background: Diagnosis of idiopathic inflammatory myopathies (IIMs) is challeng-
ing and so far no pathognomonic signs exist by imaging. Few radionuclide imaging
techniques have been tested for this purpose, mainly 99mTc-pyrophosphate planar
imaging and 18F-fluorodeoxyglucose positron emission tomography/computed
tomography (18F-FDG-PET/CT). However, 99mTc-PYP uptake has been assessed
visually and at best graded semi-quantitatively.
Objectives: We aimed for quantitative 99mTc-pyrophosphate single photon
emission computed tomography/computed tomography (99mTc-PYP-SPECT/CT)
as well as 18F-FDG-PET/CT imaging in a group of newly onset IIM patients.
Methods: Thirteen patients (mean age 62 years) with newly diagnosed, untreated
IIM underwent 99mTc-PYP SPECT/CT of the thorax, pelvis, and thighs. Seven of
the patients also had a whole-body 18F-FDG PET/CT scan. Forty-nine healthy
controls (mean age 59 years) underwent 99mTc-PYP SPECT/CT and 26 healthy
controls (mean age 57 years) had a 18F-FDG PET/CT scan done. Volumes
of interest (VOIs) covering the right biceps, triceps, and quadriceps muscles
were drawn manually on each series. Registered 99mTc-PYP counts, respectively
standardized uptake values (SUVs) of 18F-FDG were obtained from all VOIs.
Registered counts were decay- and attenuation-corrected and adjusted for body
weight and administered dose of 99mTc-PYP, yielding a parameter similar to the
SUV [g mL-1].
